Science 37 was recognized for the Participant Engagement Award for its “Pharm-to-Trial” partnership with RxE2. This decentralized vaccine trial model brings research to agricultural U.S. communities ...
MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer.
Science 37, Inc. will relocate its corporate headquarters from Culver City, CA to North Carolina’s Research Triangle region and create 250 jobs over five years. The clinical research company will ...
LOS ANGELES and NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Science 37, Inc., the Operating System for today’s agile clinical trials, announced today that it has completed its previously announced ...
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), the clinical research industry-leading Metasite™, today announced that it has been honored with the ...
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today ...
Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial ...
Science 37 has been tapped to use its virtual clinical trial tech for phase 3 trials of Synlogic’s treatment for the rare genetic metabolic disorder phenylketonuria (PKU). Under the deal, Science 37’s ...
LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Science 37 and Foundation Medicine today announced a collaboration to enable decentralized clinical research in oncology that will optimize recruitment ...
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), (“Science 37”) the Agile Clinical Trial Operating System™, today reported its financial results for ...
PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today $29 million in Series C funding led by Glynn Capital Management with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback